119 related articles for article (PubMed ID: 28040354)
1. Ultra-slow N-Acetyltransferase 2 Is Associated with Recurrence-free Time in Bladder Cancer Patients.
Selinski S; Gerullis H; Otto T; Roth E; Volkert F; Ovsiannikov D; Salem J; Moormann O; Geis BC; Niedner H; Blaszkewicz M; Hengstler JG; Golka K
Eur Urol; 2017 Jun; 71(6):994-995. PubMed ID: 28040354
[No Abstract] [Full Text] [Related]
2. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
[TBL] [Abstract][Full Text] [Related]
3. N-acetyltransferase 2 gene polymorphism as a biomarker for susceptibility to bladder cancer in Bangladeshi population.
Hosen MB; Islam J; Salam MA; Islam MF; Hawlader MZ; Kabir Y
Asia Pac J Clin Oncol; 2015 Mar; 11(1):78-84. PubMed ID: 25376209
[TBL] [Abstract][Full Text] [Related]
4. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
[TBL] [Abstract][Full Text] [Related]
5. More on adducts and addicts. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer.
Coggon D
Hum Exp Toxicol; 1995 Jun; 14(6):538-9. PubMed ID: 8519531
[No Abstract] [Full Text] [Related]
6. Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis.
Wu H; Wang X; Zhang L; Mo N; Lv Z
Clin Genitourin Cancer; 2016 Apr; 14(2):122-9. PubMed ID: 26585839
[TBL] [Abstract][Full Text] [Related]
7. Association between N-Acetyltransferase 2 Polymorphism and Bladder Cancer Risk: a Meta-Analysis in a Single Ethnic Group.
Xu WJ; Wen LP; Jiang XX; Ye LY; Meng FH; Guan S; Qian YJ; Wei JF
Clin Lab; 2017 Feb; 63(2):287-293. PubMed ID: 28182356
[TBL] [Abstract][Full Text] [Related]
8. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
9. N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort.
Pesch B; Gawrych K; Rabstein S; Weiss T; Casjens S; Rihs HP; Ding H; Angerer J; Illig T; Klopp N; Bueno-de-Mesquita B; Ros MM; Kaaks R; Chang-Claude J; Roswall N; Tjønneland A; Overvad K; Clavel-Chapelon F; Boutron-Ruault MC; Dossus L; Boeing H; Weikert S; Trichopoulos D; Palli D; Sieri S; Tumino R; Panico S; Quirós JR; González C; Sánchez MJ; Dorronsoro M; Navarro C; Barricarte A; Ljungberg B; Johansson M; Ulmert D; Ehrnström R; Khaw KT; Wareham N; Key TJ; Ferrari P; Romieu I; Riboli E; Brüning T; Vineis P
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2055-65. PubMed ID: 24092628
[TBL] [Abstract][Full Text] [Related]
10. Commentary: Reflections on G. M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned.
Rothman N; Garcia-Closas M; Hein DW
Int J Epidemiol; 2007 Feb; 36(1):23-8. PubMed ID: 17510073
[No Abstract] [Full Text] [Related]
11. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
12. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.
Hein DW
Oncogene; 2006 Mar; 25(11):1649-58. PubMed ID: 16550165
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.
Hsieh FI; Pu YS; Chern HD; Hsu LI; Chiou HY; Chen CJ
Br J Cancer; 1999 Oct; 81(3):537-41. PubMed ID: 10507782
[TBL] [Abstract][Full Text] [Related]
14. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.
Carreón T; Ruder AM; Schulte PA; Hayes RB; Rothman N; Waters M; Grant DJ; Boissy R; Bell DA; Kadlubar FF; Hemstreet GP; Yin S; LeMasters GK
Int J Cancer; 2006 Jan; 118(1):161-8. PubMed ID: 16003747
[TBL] [Abstract][Full Text] [Related]
15. N-acetyltransferase 1*10 genotype in bladder cancer patients.
Höhne S; Gerullis H; Blaszkewicz M; Selinski S; Hengstler JG; Otto T; Golka K
J Toxicol Environ Health A; 2017; 80(7-8):417-422. PubMed ID: 28696911
[TBL] [Abstract][Full Text] [Related]
16. Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study.
Lubin JH; Kogevinas M; Silverman D; Malats N; Garcia-Closas M; Tardón A; Hein DW; Garcia-Closas R; Serra C; Dosemeci M; Carrato A; Rothman N
Int J Epidemiol; 2007 Feb; 36(1):236-41. PubMed ID: 17510079
[TBL] [Abstract][Full Text] [Related]
17. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
Cascorbi I; Roots I; Brockmöller J
Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
[TBL] [Abstract][Full Text] [Related]
18. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer.
Deitz AC; Rothman N; Rebbeck TR; Hayes RB; Chow WH; Zheng W; Hein DW; García-Closas M
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1543-6. PubMed ID: 15342459
[TBL] [Abstract][Full Text] [Related]
19. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
[TBL] [Abstract][Full Text] [Related]
20. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.
Lower GM; Nilsson T; Nelson CE; Wolf H; Gamsky TE; Bryan GT
Environ Health Perspect; 1979 Apr; 29():71-9. PubMed ID: 510245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
